These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

716 related items for PubMed ID: 19451711

  • 1. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC.
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [Abstract] [Full Text] [Related]

  • 2. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
    Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A.
    Melanoma Res; 2010 Dec; 20(6):501-6. PubMed ID: 20859231
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP.
    Oncologist; 2005 Dec; 10(6):392-8. PubMed ID: 15967833
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.
    Cancer; 2002 Jan 15; 94(2):470-6. PubMed ID: 11900232
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
    Vestermark LW, Larsen S, Lindeløv B, Bastholt L.
    Acta Oncol; 2008 Jan 15; 47(8):1526-30. PubMed ID: 18607876
    [Abstract] [Full Text] [Related]

  • 6. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C.
    Cancer; 2005 Jun 15; 103(12):2584-9. PubMed ID: 15887220
    [Abstract] [Full Text] [Related]

  • 7. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
    Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E.
    Cancer; 2010 Aug 01; 116(15):3683-91. PubMed ID: 20564083
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM.
    Urology; 2004 Jun 01; 63(6):1061-5. PubMed ID: 15183950
    [Abstract] [Full Text] [Related]

  • 9. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    Shiloni E, Pouillart P, Janssens J, Splinter T, Di Peri T, Symann M, Roest GJ, Palmer PA, Franks CR.
    Eur J Cancer Clin Oncol; 1989 Jun 01; 25 Suppl 3():S45-9. PubMed ID: 2697579
    [Abstract] [Full Text] [Related]

  • 10. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
    McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E.
    J Clin Oncol; 2008 May 01; 26(13):2178-85. PubMed ID: 18445842
    [Abstract] [Full Text] [Related]

  • 11. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G.
    In Vivo; 2002 May 01; 16(2):93-6. PubMed ID: 12073777
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
    Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM, Kirkwood JM.
    Cancer; 2009 Feb 15; 115(4):859-68. PubMed ID: 19140204
    [Abstract] [Full Text] [Related]

  • 14. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
    Agarwala SS, Ferri W, Gooding W, Kirkwood JM.
    Cancer; 1999 May 01; 85(9):1979-84. PubMed ID: 10223239
    [Abstract] [Full Text] [Related]

  • 15. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
    Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, González-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E, Menssen HD, Neri D, Garbe C.
    Clin Cancer Res; 2011 Dec 15; 17(24):7732-42. PubMed ID: 22028492
    [Abstract] [Full Text] [Related]

  • 16. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
    Tan EH, Ang PT.
    Singapore Med J; 1996 Apr 15; 37(2):165-7. PubMed ID: 8942255
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
    Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, Tchekmedyian NS, Sondak VK, Southwest Oncology Group.
    Cancer; 2004 Apr 15; 100(8):1699-704. PubMed ID: 15073859
    [Abstract] [Full Text] [Related]

  • 20. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Pyrhönen S, Hahka-Kemppinen M, Muhonen T, Nikkanen V, Eskelin S, Summanen P, Tarkkanen A, Kivelä T.
    Cancer; 2002 Dec 01; 95(11):2366-72. PubMed ID: 12436444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.